Qiagen NV
XMUN:QIA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Q
|
Qiagen NV
XMUN:QIA
|
NL |
Qiagen NV
Qiagen makes the tools that scientists and clinical labs use to prepare, test, and analyze biological samples such as blood, tissue, and swabs. Its products include sample preparation kits, test reagents, instruments, and software that help extract DNA or RNA, detect genetic material, and support molecular testing. In simple terms, Qiagen sits in the middle of the testing workflow: it helps turn raw samples into results that can be used for research or diagnosis. Its main customers are hospitals, reference laboratories, research institutions, biotech companies, pharmaceutical firms, and public health labs. These buyers use Qiagen products for disease testing, infectious disease detection, genetic research, drug development, and lab automation. The company makes money by selling consumable kits and reagents, plus instruments and related services that customers need to keep running those tests. What makes Qiagen different is that it is not a drug maker or a hospital operator; it is a specialized supplier to the diagnostics and life sciences industry. Its business depends on repeat usage, because many of its products are consumed every time a test or experiment is performed. That gives the company a steady role in the testing value chain, especially where accuracy, sample handling, and reliable lab workflows matter.
Qiagen makes the tools that scientists and clinical labs use to prepare, test, and analyze biological samples such as blood, tissue, and swabs. Its products include sample preparation kits, test reagents, instruments, and software that help extract DNA or RNA, detect genetic material, and support molecular testing. In simple terms, Qiagen sits in the middle of the testing workflow: it helps turn raw samples into results that can be used for research or diagnosis.
Its main customers are hospitals, reference laboratories, research institutions, biotech companies, pharmaceutical firms, and public health labs. These buyers use Qiagen products for disease testing, infectious disease detection, genetic research, drug development, and lab automation. The company makes money by selling consumable kits and reagents, plus instruments and related services that customers need to keep running those tests.
What makes Qiagen different is that it is not a drug maker or a hospital operator; it is a specialized supplier to the diagnostics and life sciences industry. Its business depends on repeat usage, because many of its products are consumed every time a test or experiment is performed. That gives the company a steady role in the testing value chain, especially where accuracy, sample handling, and reliable lab workflows matter.
Mixed quarter: QIAGEN said Q1 sales were below plan, but adjusted diluted EPS of $0.54 came in line with outlook thanks to disciplined cost control.
QuantiFERON hit: The main disappointment was QuantiFERON, where sales fell 5% CER because immigration-related testing demand dropped sharply in the U.S. and the Middle East.
Outlook cut: Full-year 2026 guidance was lowered to 1% to 2% CER sales growth from at least 5%, while adjusted diluted EPS guidance was trimmed to at least $2.43 from at least $2.50.
Still confident: Management said the QuantiFERON issue is isolated to immigration volumes and expects sequential improvement through the year, with stronger growth in the second half.
Margin intact: QIAGEN kept its full-year adjusted EBIT margin target of 29.5% and said Q2 should already be north of 29%, helped by efficiency programs and mix.
Life Sciences cautious: The company also turned more cautious on U.S. life sciences spending, especially in research, academia, OEM, enzymes and oligos.
Pipeline support: New launches in sample technologies, QIAcuity, QIAstat and Parse were described as important second-half growth drivers, with Parse now expected to exceed its $40 million sales target for 2026.
